{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:52:42Z","timestamp":1782150762740,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To explore and analyze post-marketing adverse drug event (ADE) signals for voriconazole, posaconazole, and isavuconazole, and to compare the safety differences among the three drugs, aiming to provide insights for rational clinical use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the Open Vigil 2.1 online tool, extract adverse drug event (ADE) report data for voriconazole, posaconazole, and isavuconazole from the U.S. Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) database from the time the drugs were marketed up to the third quarter of 2023. Employ the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) methods for data mining. Filter out ADE signals detected by both the ROR and PRR methods, and categorize these ADE signals by System Organ Class (SOC) according to the Medical Dictionary for Regulatory Activities (MedDRA 26.0).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 8,898 ADE reports with voriconazole as the primary suspect drug were retrieved, 1,948 for posaconazole, and 944 for isavuconazole. From the basic analysis of the adverse event reports, male patients (50.31%) outnumber female patients (32.11%). In terms of age, the majority of patients are over 45 years old (52.72%). The reports primarily come from the United States, Japan, France, China, and other countries. A total of 607 ADE signals were identified, with 402 for voriconazole, 159 for posaconazole, and 46 for isavuconazole. Voriconazole ADEs primarily involved the following SOCs: Investigations (9.45%), Eye Disorders (8.46%), and Nervous System Disorders (7.21%); Posaconazole ADEs primarily involved the following SOCs: Investigations (13.84%), General Disorders and Administration Site Conditions (11.95%), and Nervous System Disorders (6.29%); Isavuconazole ADEs primarily involved the following SOCs: General Disorders and Administration Site Conditions (15.22%), Hepatobiliary Disorders (10.87%), and Blood and Lymphatic System Disorders (10.87%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Voriconazole, posaconazole, and isavuconazole all potentially pose safety risks related to hepatobiliary disorders and cardiac disorders. Additionally, voriconazole carries a higher safety risk for eye disorders and nervous system disorders. Newly discovered ADE signals not mentioned in the drug package inserts include voriconazole-induced rhabdomyolysis, posaconazole-induced peripheral neuropathy, and isavuconazole-induced visual impairment and mental confusion. These findings are significant for guiding rational clinical use of these medications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1462510","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:00:55Z","timestamp":1737615655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yalan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijpam.2021.03.007","article-title":"Voriconazole-induced severe hypokalemic rhabdomyolysis: a case report","volume":"9","author":"Alawfi","year":"2022","journal-title":"Int. J. Pediatr. Adolesc. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigi-lance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/cid\/ciz159","article-title":"Lack of toxicity with long-term isavuconazole use in patients with hematologic malignancy","volume":"69","author":"DiPippo","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/toxsci\/kfx029","article-title":"Hepatocellular toxicity of imidazole and triazole antimycotic agents","volume":"157","author":"Haegler","year":"2017","journal-title":"Toxicol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.1354413544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin. Transpl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"ofz031","DOI":"10.1093\/ofid\/ofz031","article-title":"Treatment of posaconazole-induced peripheral neuropathy with methylprednisolone and magnesium infusions: a case report","volume":"6","author":"Hussain","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/mmy\/myy052","article-title":"Broad spectrum triazoles for invasive mould infections in adults: which drug and when?","volume":"57","author":"Jenks","year":"2019","journal-title":"Med. Mycol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jamia\/ocv153","article-title":"OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data","volume":"23","author":"Kass-Hout","year":"2016","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1097\/CM9.0000000000001562","article-title":"Assessing taxane-associated adverse events using the FDA adverse event reporting system database","volume":"134","author":"Lao","year":"2021","journal-title":"Chin. Med. J. Engl."},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3760\/cma.j.issn.1007-3418.2017.01.013","article-title":"Rhabdomyolysis caused by voriconazole in treatment of severe hepatitis complicated by pulmonary fungal infection: a case report","volume":"25","author":"Li","year":"2017","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/myc.1273112731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"B14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.12659\/ajcr.896946","article-title":"Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report","volume":"17","author":"Panos","year":"2016","journal-title":"Am. J. Case Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jac\/dkw465","article-title":"Acute reversible pancreatitis induced by posaconazole","volume":"72","author":"Pilmis","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/2168479014555913","article-title":"openFDA: an open question","volume":"49","author":"Pitts","year":"2015","journal-title":"Ther. Innov. Regul. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e254790","DOI":"10.1136\/bcr-2023-254790","article-title":"Voriconazole-induced psychosis in rhino-orbital invasive aspergillosis","volume":"16","author":"Rekha","year":"2023","journal-title":"BMJ Case Rep."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12712","article-title":"Use of isavuconazole in a patient with voriconazole-induced QTc prolongation","volume":"19","author":"Trang","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"115157","DOI":"10.1016\/j.taap.2020.115157","article-title":"Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress","volume":"403","author":"Wu","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1021\/acs.chemrestox.9b00176","article-title":"Metabolomics investigation of voriconazole-induced hepatotoxicity in mice","volume":"32","author":"Wu","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/bmj.320.7243.1158","article-title":"Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation","volume":"320","author":"Yap","year":"2000","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000359952","article-title":"Effects of multiple doses of voriconazole on the vision of healthy volunteers: a double-blind, placebo-controlled study","volume":"52","author":"Zrenner","year":"2014","journal-title":"Ophthalmic Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1462510\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:00:58Z","timestamp":1737615658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1462510\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":22,"alternative-id":["10.3389\/fphar.2025.1462510"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1462510","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1462510"}}